# Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome

> **NCT02221271** · PHASE3 · COMPLETED · sponsor: **Nihon Pharmaceutical Co., Ltd** · enrollment: 22 (actual)

## Conditions studied

- Guillain-Barré Syndrome

## Interventions

- **DRUG:** NPB-01

## Key facts

- **NCT ID:** NCT02221271
- **Lead sponsor:** Nihon Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221271, "Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02221271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*